Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow CUE by emailGet an email when CUE pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about CUE, unsubscribe in one click. Privacy
📣 What CUE Says Is Next
by year-end 2026 · “Company anticipates submitting an IND to the FDA and initiating a Phase 1 clinical study by year-end 2026 Financial and Corporate”
Company press release, Aug 14, 2026 · SEC filing
by the end of the year · “We look forward to anticipated CUE-221 Phase 2 data by the end of this quarter and remain on track to initiate a CUE-401 Phase 1 study by the end of the year.” Business, Financial and Leadership Highlights Milestones CUE-221”
Company press release, Aug 14, 2026 · SEC filing
2H 2026 · “Ascendant-221 is currently being evaluated by Ascendant Health’s related company, Genesis Life Sciences, in a Phase 2 placebo and active comparator-controlled dose-ranging study in chronic spontaneous urticaria (CSU) in China (China Study) with clinical results expected in 2H 2026.”
Company press release, May 1, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full CUE picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CUE and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.